Editor's Note Joint guidance from key US medical associations advises that most patients on GLP-1 weight-loss medications, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), may safely continue these drugs before surgery, HealthDay News reported October 31. Concerns had emerged about potential risks associated with these medications due to their…

Read More

Editor's Note Combining newer weight loss drugs with bariatric surgery is the most cost-effective long-term strategy for treating obesity, according to research presented at the American College of Surgeons Clinical Congress 2024. Medical Xpress reported on the findings October 18. According to the article, researchers from Northwestern Medicine evaluated the…

Read More

Editor's Note Patients using GLP-1 receptor agonists (GLP-1 RAs) have a higher risk of food retention during esophagogastroduodenoscopy (EGD) when performed alone, but not when combined with a colonoscopy, according to a retrospective study from Cedars-Sinai Medical Center. MedPage Today reported the news October 1. The study included 70 patients…

Read More

Editor's Note Bariatric surgery significantly reduces the progression of chronic kidney disease (CKD) in patients with type 2 diabetes and obesity compared to those on GLP-1 diabetes medications, according to a study from Cleveland Clinic. Published in Annals of Surgery and detailed in a September 20 announcement from Cleveland Clinic,…

Read More

Editor's Note Patients prescribed a glucagon-like peptide-1 agonist (GLP-1) showed higher postoperative infection rates after ankle-fusion procedures in a study presented at the annual meeting of the American Orthopaedic Foot & Ankle Society. Healio reported the news September 20.   Conducted by a team at the Milton S. Hershey Medical…

Read More

Editor's Note Findings to be presented at the American Heart Association's Hypertension Scientific Sessions 2024 suggest bariatric surgery may offer more effective long-term control of high blood pressure for people with obesity compared to medications and lifestyle changes, according to a September 5 report in News Medical. According to the…

Read More

Editor's Note A shuttered bariatric surgery center in Oklahoma last month is just one example of how the rise of Glucagon-like peptide-1 (GLP-1) agonists are reshaping health systems’ investments, Axios reported August 13. Rather than “massive hospital towers with cardiology clinics, dialysis beds and joint replacement centers,” the focus is…

Read More

Editor's Note For diabetic patients with obesity and chronic kidney disease (CKD), metabolic bariatric surgery could protect the kidneys better than therapy with glucagon-like peptide-1 receptor agonists (GLP-1RA), according to research published in the September issue of the Annals of Surgery. Conducted at a large US health system, the study…

Read More

Editor's Note Healthcare costs are expected to rise between 7% and 8% in 2025, according to a report from PwC's Health Research Institute. As detailed in a July 17 article from Fierce Healthcare, PwC projections for an 8% increase in the group market and 7.5% in the individual market would…

Read More

Editor's Note Roux-en-Y gastric bypass surgery kept type 2 diabetes in remission for up to 15 years and maintained most of the weight loss for up to 20 years in a long-term study, according to a June 12 report in SciTech Daily. Presented the same day at The American Society…

Read More